EPS Creative Health Technology Group Limited

As of September 30, 2019, EPS Creative Health Technology Group Limited carries a market capitalization of 270.00M, placing it among publicly traded companies globally. Its enterprise value stands at 201.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2019, EPS Creative Health Technology Group Limited has 500.00M shares outstanding.

As of September 30, 2019, EPS Creative Health Technology Group Limited trades at a trailing price-to-earnings ratio of 7.77. The price-to-sales ratio is 0.50, and the price-to-book ratio stands at 2.20.

As of September 30, 2019, EPS Creative Health Technology Group Limited trades at an EV/EBITDA multiple of 5.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 201.77M versus a market cap of 270.00M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2019, EPS Creative Health Technology Group Limited maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.33, indicating elevated leverage, while an interest coverage ratio of 255.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2019, EPS Creative Health Technology Group Limited posted a return on equity (ROE) of 31.81, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 28.01 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 30.59, useful for judging operating efficiency across full business cycles. The company generates approximately 8.33M in revenue per employee across its workforce of 64.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.38 indicates how many times EPS Creative Health Technology Group Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2019, EPS Creative Health Technology Group Limited recorded 7.23M in income tax expense. That works out to an effective tax rate of 17.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 41.97M, leaving 34.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, EPS Creative Health Technology Group Limited's stock has gained approximately 17.17% over the past 52 weeks. The 50-day moving average sits at 0.58, while the 200-day moving average is 0.57.

Over the twelve months ended September 30, 2019, EPS Creative Health Technology Group Limited generated 537.50M in revenue and converted that into 34.74M in net income, yielding earnings per share of 0.07. EBITDA reached 40.05M, while operating income came in at 41.17M.

As of September 30, 2019, EPS Creative Health Technology Group Limited holds 71.08M in cash and equivalents against 2.85M in total debt, resulting in a net debt position of -71.08M. Total book value stands at 122.52M, with working capital of 118.59M providing operational flexibility.

Over the twelve months ended September 30, 2019, EPS Creative Health Technology Group Limited posted a gross margin of 18.65, reflecting its pricing power and cost economics. The operating margin of 7.66 and net profit margin of 6.46 provide insight into operational efficiency.

As of September 30, 2019, EPS Creative Health Technology Group Limited has an Altman Z-Score of 4.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.